Daniel Jackson | Global Head, Payer Evidence Synthesis
UCB

Daniel Jackson is the Global Head of Payer Evidence Synthesis at UCB, where he leads the design and execution of payer evidence generation strategies that support sustainable patient access to innovative biopharmaceutical therapies across international markets. He directs global health economics and outcomes research initiatives, specialising in the integration of economic evidence to build compelling value propositions aligned with evolving payer and health technology assessment (HTA) requirements. Holding a PhD in Health Economics, Daniel combines deep technical expertise with strategic leadership, overseeing high-performing teams to deliver impactful outcomes in pricing, reimbursement, and market access. His work consistently supports positive payer decisions and commercial growth by demonstrating the real-world impact of UCB’s portfolio across diverse healthcare systems. Daniel’s insights are further informed by his advisory roles with the UK’s Joint Committee on Vaccination and Immunisation (JCVI) and as an industry representative on the NICE Technology Appraisal Appeals Panel, providing a nuanced understanding of health policy and payer decision-making. A strong advocate for cross-functional collaboration, Daniel champions the early integration of payer perspectives and real-world evidence in the product lifecycle to align research, regulatory, and commercial strategies. He is committed to mentoring emerging leaders and advancing innovative, sustainable healthcare solutions on a global scale.